Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Int Immunopharmacol ; 110: 108942, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35810489

ABSTRACT

The elderly population is growing rapidly all over the world. The aging population has brought great medical pressure to the society. It is found that aging is one of the pathogenic factors of liver fibrosis and liver cancer. Therefore, it is very important to explore functional foods with anti-aging, anti-fibrosis and anti-liver cancer effect. Therefore, in this work, we studied the potential effects of Canthaxanthin on liver aging, liver fibrosis and liver cancer. Firstly, we established the aging modelof liver cells by using H2O2. On this basis, the anti-aging effect of Canthaxanthin was analyzed, and the results showed that Canthaxanthin could significantly alleviate the aging of liver cells through Sa-ß-Gal staining and analysis of the expression of aging related markers. In vivo, aged mice wereused as the animal model for studying the effect of anti-aging of Canthaxanthin. The results showed that Canthaxanthin could significantly alleviate the aging of liver in vivo. Further study show that Canthaxanthin may alleviatethe aging of liver cells by regulating SIRT6; Secondly, we evaluated the effect of Canthaxanthin on liver fibrosis. A model of liver fibrosis was established by CCl4. Masson and Sirius red staining showed that Canthaxanthin could significantly reduce the fibrosis area. Additionally, the level of liver inflammation was also reduced; Thirdly, the effect of Canthaxanthin on hepatoma cells has also been investigated. The resultsshowed that Canthaxanthin could promote the apoptosis of hepatoma cells in vivo and in vitro. To sum up, these results show that canthaxanthin can significantly alleviate liver aging and fibrosis, and Canthaxanthin can also promote the apoptosis of liver cancer cells, indicating that Canthaxanthin can be used as a potential drug or health food for the treatment of liveraging related diseases.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Sirtuins , Aged , Aging , Animals , Canthaxanthin/metabolism , Canthaxanthin/therapeutic use , Carbon Tetrachloride , Humans , Hydrogen Peroxide , Inflammation/metabolism , Liver Cirrhosis/metabolism , Mice , Oxidative Stress , Sirtuins/metabolism
2.
Arq. bras. med. vet. zootec ; 68(5): 1177-1182, set.-out. 2016. tab
Article in Portuguese | LILACS, VETINDEX | ID: biblio-827881

ABSTRACT

Objetivou-se avaliar os efeitos de antioxidantes suplementados às dietas de galos de matrizes pesadas em idade avançada sobre as características reprodutivas. Foram utilizados galos da linhagem Cobb com 47 semanas de idade. Estes foram distribuídos em quatros tratamentos, de acordo com a adição de antioxidante à dieta, sendo: A = grupo controle (sem suplementação antioxidante); B = suplementação de 9ppm de citranaxantina; C = suplementação de 6ppm de cantaxantina e D = 150ppm de vitamina E. Foram avaliadas as características seminais, tais como volume, vigor, motilidade e concentração, a composição de ácidos graxos do sêmen (saturados, insaturados, monoinsaturados, poli-insaturados, ômega 3, ômega 6 e ômega 9) e a correlação entre o peso dos testículos e o peso dos galos. Não foram observados efeitos das substâncias antioxidantes testadas sobre os parâmetros reprodutivos avaliados. Os antioxidantes avaliados não influenciam as respostas reprodutivas de machos reprodutores de matrizes pesadas em idade avançada.(AU)


This study aimed to evaluate the effect of antioxidant supplementation in diets of aging broiler breeder roosters on reproductive characteristics. Cobb roosters were divided into four groups, according to antioxidant addition, where: A = control group (without antioxidant supplementation); B = 9ppm of citranaxanthin; C = 6ppm of canthaxanthin, and D = 150ppm of vitamin E. Seminal characteristics (volume, force, motility and concentration), semen fatty acid composition (saturated, unsaturated, monounsaturated, polyunsaturated, ω3, ω6 and ω9), and the correlation between testis weight with rooster weight were evaluated. No effects of the antioxidants tested were observed. The antioxidants do not influence the reproductive responses of aging male broiler breeder.(AU)


Subject(s)
Animals , Male , Animal Feed/analysis , Antioxidants/analysis , Chickens , Dietary Supplements/statistics & numerical data , Semen Analysis/veterinary , Canthaxanthin/therapeutic use , Vitamin E/administration & dosage
3.
J Nutr ; 131(5): 1574-80, 2001 May.
Article in English | MEDLINE | ID: mdl-11340118

ABSTRACT

Both estrogen-receptor (ER) positive MCF-7 and ER-negative Hs578T and MDA-MB-231 human breast cancer cells were treated with carotenoids (beta-carotene, canthaxanthin and lycopene) and retinoids (all-trans-, 9-cis- and 13-cis-retinoic acid and all-trans-retinol). Among carotenoids, beta-carotene significantly reduced the growth of MCF-7 and Hs578T cells, and lycopene inhibited the growth of MCF-7 and MDA-MB-231 cells. Canthaxanthin did not affect the proliferation of any of the three cell lines. All-trans- and 9-cis-retinoic acid significantly reduced the growth of both MCF-7 and Hs578T cells, whereas 13-cis-retinoic acid and all-trans-retinol had a significant effect only on MCF-7 cells. MCF-7 and Hs578T cells treated with all-trans-retinoic acid (all-t-RA) were further studied for the mechanism behind growth inhibition. Retinoic acid receptors alpha and gamma (RARalpha, gamma) in MCF-7 cells and RARalpha, beta and gamma in Hs578T cells were not induced by all-t-RA treatment at either the protein or mRNA level. Hs578T cells treated with all-t-RA had significantly more cells in the G0/G1 stage of the cell cycle, but the same was not observed for MCF-7 cells. All-t-RA induced a dose-dependent cell death in MCF-7 cells, which may be a necrotic phenomenon. These results demonstrate that ER status is an important, although not essential factor for breast cancer cell response to carotenoid and retinoid treatments, and the mode of action of all-t-RA in MCF-7 and Hs578T cells is not through the induction of RAR. Other mechanistic pathways that are either followed by or concomitant with growth inhibition are possible.


Subject(s)
Apoptosis/drug effects , Breast Neoplasms/drug therapy , Carotenoids/therapeutic use , Cell Division/drug effects , Receptors, Estrogen/drug effects , Retinoids/therapeutic use , Antioxidants/pharmacology , Blotting, Northern , Canthaxanthin/therapeutic use , Female , Flow Cytometry , Humans , Tumor Cells, Cultured/drug effects
4.
Biometrics ; 56(4): 1068-75, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11129462

ABSTRACT

In some types of cancer chemoprevention experiments and short-term carcinogenicity bioassays, the data consist of the number of observed tumors per animal and the times at which these tumors were first detected. In such studies, there is interest in distinguishing between treatment effects on the number of tumors induced by a known carcinogen and treatment effects on the tumor growth rate. Since animals may die before all induced tumors reach a detectable size, separation of these effects can be difficult. This paper describes a flexible parametric model for data of this type. Under our model, the tumor detection times are realizations of a delayed Poisson process that is characterized by the age-specific tumor induction rate and a random latency interval between tumor induction and detection. The model accommodates distinct treatment and animal-specific effects on the number of induced tumors (multiplicity) and the time to tumor detection (growth rate). A Gibbs sampler is developed for estimation of the posterior distributions of the parameters. The methods are illustrated through application to data from a breast cancer chemoprevention experiment.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Drug Screening Assays, Antitumor/methods , Neoplasms, Experimental/pathology , Neoplasms, Experimental/prevention & control , Vitamin A/analogs & derivatives , 9,10-Dimethyl-1,2-benzanthracene , Animals , Biometry/methods , Canthaxanthin/therapeutic use , Diterpenes , Female , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Mammary Neoplasms, Experimental/prevention & control , Models, Statistical , Rats , Rats, Sprague-Dawley , Retinyl Esters , Vitamin A/therapeutic use
5.
Anticancer Res ; 19(3A): 1849-53, 1999.
Article in English | MEDLINE | ID: mdl-10470126

ABSTRACT

The anticancer activities of beta-carotene, astaxanthin and canthaxanthin against the growth of mammary tumors were studied in female eight-wk-old BALB/c mice. The mice were fed a synthetic diet containing 0, 0.1 or 0.4% beta-carotene, astaxanthin or canthaxanthin. After 3 weeks, all mice were inoculated with 1 x 10(6) WAZ-2T tumor cells into the mammary fat pad. All animals were killed on 45 d after inoculation with the tumor cells. No carotenoids were detectable in the plasma or tumor tissues of unsupplemented mice. Concentrations of plasma astaxanthin (20 to 28 mumol/L) were greater (P < 0.05) than that of beta-carotene (0.1 to 0.2 mumol/L) and canthaxanthin (3 to 6 mmol/L). However, in tumor tissues, the concentration of canthaxanthin (4.9 to 6.0 nmol/g) was higher than that of beta-carotene (0.2 to 0.5 nmol/g) and astaxanthin (1.2 to 2.7 nmol/g). In general, all three carotenoids decreased mammary tumor volume. Mammary tumor growth inhibition by astaxanthin was dose-dependent and was higher than that of canthaxanthin and beta-carotene. Mice fed 0.4% beta-carotene or canthaxanthin did not show further increases in tumor growth inhibition compared to those fed 0.1% of each carotenoid. Lipid peroxidation activity in tumors was lower (P < 0.05) in mice fed 0.4% astaxanthin, but not in those fed beta-carotene and canthaxanthin. Therefore, beta-carotene, canthaxanthin and especially astaxanthin inhibit the growth of mammary tumors in mice; their anti-tumor activity is also influenced by the supplemental dose.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Canthaxanthin/therapeutic use , Mammary Neoplasms, Experimental/prevention & control , beta Carotene/analogs & derivatives , beta Carotene/therapeutic use , Administration, Oral , Animals , Anticarcinogenic Agents/administration & dosage , Anticarcinogenic Agents/blood , Anticarcinogenic Agents/pharmacokinetics , Antioxidants/administration & dosage , Antioxidants/analysis , Antioxidants/pharmacokinetics , Antioxidants/therapeutic use , Canthaxanthin/administration & dosage , Canthaxanthin/blood , Canthaxanthin/pharmacokinetics , Cell Membrane/drug effects , Diet , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Intestinal Absorption , Lipid Peroxidation/drug effects , Mammary Neoplasms, Experimental/blood , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Thiobarbituric Acid Reactive Substances/analysis , Xanthophylls , beta Carotene/administration & dosage , beta Carotene/blood , beta Carotene/pharmacokinetics
6.
Australas J Dermatol ; 39(3): 179-82, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9737047

ABSTRACT

Erythropoietic protoporphyria is a rare photodermatosis for which treatment options are limited. The present report describes the clinical features of a patient with erythropoietic protoporphyria and liver function test abnormalities associated with treatment with beta-carotene. Subsequent treatment with narrow-band UVB phototherapy resulted in marked subjective improvement in photosensitivity, which was confirmed by abolition of demonstrated abnormalities on monochromator phototesting. The therapeutic options for photosensitivity in erythropoietic protoporphyria are reviewed and discussed.


Subject(s)
Porphyria, Hepatoerythropoietic/radiotherapy , Ultraviolet Therapy , Antioxidants/therapeutic use , Canthaxanthin/therapeutic use , Chemical and Drug Induced Liver Injury , Child , Feces/chemistry , Humans , Male , Porphyria, Hepatoerythropoietic/drug therapy , Protoporphyrins/analysis , Protoporphyrins/blood , Protoporphyrins/urine , Ultraviolet Rays/classification , beta Carotene/adverse effects , beta Carotene/therapeutic use
7.
Nutr Cancer ; 28(2): 199-205, 1997.
Article in English | MEDLINE | ID: mdl-9290128

ABSTRACT

The antitumor effect of canthaxanthin in BALB/c mice bearing a transplantable thymoma was investigated. Male or female mice received two different doses of canthaxanthin (7 or 14 micrograms/g body wt/day) starting 15 days before tumor inoculation (7 x 10(7) cells i.p.). Canthaxanthin treatment delayed the appearance of macroscopic ascites and prolonged animal survival. This effect was dose dependent and more evident in females than in males. It appeared only when the carotenoid was administered before tumor transplantation. The antitumor efficacy of the carotenoid was related to its tissue incorporation. Canthaxanthin was incorporated in a dose-dependent manner in liver and thymoma cells and to a larger extent in females than in males. Our study shows the antitumor efficacy of canthaxanthin in vivo against a transplantable murine thymoma and points out the importance of dose, administration timing, and sex in the antitumor efficacy of this compound.


Subject(s)
Antioxidants/therapeutic use , Ascites/prevention & control , Canthaxanthin/therapeutic use , Thymoma/drug therapy , Thymus Neoplasms/drug therapy , Administration, Oral , Animals , Antioxidants/administration & dosage , Antioxidants/analysis , Ascites/pathology , Canthaxanthin/administration & dosage , Canthaxanthin/analysis , Cohort Studies , Dose-Response Relationship, Drug , Female , Liver/chemistry , Male , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Thymoma/pathology , Thymus Neoplasms/pathology , Tumor Cells, Cultured
8.
Nutr Cancer ; 26(2): 203-8, 1996.
Article in English | MEDLINE | ID: mdl-8875557

ABSTRACT

Using mouse skin papilloma as a model system, we examined whether the antitumorigenic activity of carotenoids was related to their provitamin A activity. Oral administration of canthaxanthin (CX) or beta-carotene at 200 mg/kg/day for 14 days significantly reduced the cumulative size of papillomas induced on the skin by 9,10-dimethyl-1,2-benzanthracene (p < 0.05), after the accumulation of these carotenoids in the tumors. The levels of a protooncogene, c-myc, were simultaneously suppressed in papillomas in carotenoid-treated mice. Because CX cannot be converted metabolically to retinoids, these results suggested that CX directly inhibited the growth of papillomas. Neither the accumulation of retinoids nor the expression of a retinoic acid-inducible gene, retinoic acid receptor-beta, was found in papillomas of CX- and beta-carotene-treated mice, suggesting that, like CX, beta-carotene might exert the tumor-suppressing effect without being converted to retinoids. Thus a certain antitumorigenic activity of carotenoids appears not necessarily to require their provitamin A activity.


Subject(s)
Canthaxanthin/therapeutic use , Papilloma/drug therapy , Skin Neoplasms/drug therapy , Tretinoin/metabolism , beta Carotene/therapeutic use , 9,10-Dimethyl-1,2-benzanthracene , Animals , Canthaxanthin/administration & dosage , Canthaxanthin/metabolism , Female , Gene Expression/drug effects , Mice , Papilloma/metabolism , Papilloma/pathology , Proto-Oncogene Proteins c-myc/metabolism , RNA, Messenger/metabolism , Receptors, Retinoic Acid/genetics , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Tretinoin/pharmacology , beta Carotene/administration & dosage , beta Carotene/metabolism
9.
Carcinogenesis ; 16(12): 2957-63, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8603470

ABSTRACT

The modulating effects of dietary feeding of two xanthophylls, astaxanthin (AX) and canthaxanthin (CX) during the postinitiation phase on colon carcinogenesis initiated with azoxymethane (AOM) were investigated in male F344 rats. Animals were initiated with AOM by weekly s.c. injections of 15 mg/kg body wt for 3 weeks and then they were fed the diets containing AX or CX at concentrations of 100 and 500 p.p.m. for 34 weeks. The others contained the groups of rats treated with AX or CX alone and untreated. At the end of the study (week 37), the incidence and multiplicity of neoplasms (adenoma and adenocarcinoma) in the large intestine of rats initiated with AOM and followed by AX or CX containing diet at a high dose (500 p.p.m.) were significantly smaller than those of rats given AOM alone (P < 0.001). In addition, AX or CX feeding significantly inhibited the development of aberrant crypt foci induced by AOM. Dietary exposure to AX or CX also decreased cell proliferation activity as revealed by measuring 5'-bromodeoxyuridine-labeling index as crypt cells, colonic mucosal ornithine decarboxylase activity and blood polyamine levels. These results indicate that AX and CX are possible chemopreventers for carcinogenesis of colon in addition to urinary bladder and oral cavity and such effects may be partly due to suppression of cell proliferation.


Subject(s)
Azoxymethane , Canthaxanthin/therapeutic use , Carcinogens , Carotenoids/therapeutic use , Colonic Neoplasms/prevention & control , beta Carotene/analogs & derivatives , Animals , Azoxymethane/antagonists & inhibitors , Bromodeoxyuridine , Canthaxanthin/administration & dosage , Carcinogens/antagonists & inhibitors , Carotenoids/administration & dosage , Colon/enzymology , Colonic Neoplasms/chemically induced , Colonic Neoplasms/epidemiology , Diet , Incidence , Intestinal Mucosa/enzymology , Male , Ornithine Decarboxylase/metabolism , Polyamines/blood , Rats , Rats, Inbred F344 , Xanthophylls
10.
Cancer Res ; 55(18): 4059-64, 1995 Sep 15.
Article in English | MEDLINE | ID: mdl-7664280

ABSTRACT

The chemopreventive effects of two xanthophylls, astaxanthin (AX) and canthaxanthin (CX) on oral carcinogenesis induced by 4-nitroquinoline 1-oxide (4-NQO) was investigated in male F344 rats. Rats were given 20 ppm of 4-NQO in their drinking water for 8 weeks to induce oral neoplasms or preneoplasms. Animals were fed diets containing 100 ppm AX or CX during the initiation or postinitiation phase of 4-NQO-induced oral carcinogenesis. The others contained the groups of rats treated with AX or CX alone and untreated. At the end of the study (week 32), the incidences of preneoplastic lesions and neoplasms in the oral cavity of rats treated with 4-NQO and AX or CX were significantly smaller than those of rats given 4-NQO alone (P < 0.001). In particular, no oral neoplasms developed in rats fed AX and CX during the 4-NQO exposure and in those given CX after the 4-NQO administration. Similarly, the incidences of oral preneoplastic lesions (hyperplasia and dysplasia) in rats treated with 4-NQO and AX or CX were significantly smaller than that of the 4-NQO-alone group (P < 0.05). In addition to such tumor inhibitory potential, dietary exposure of AX or CX decreased cell proliferation activity in the nonlesional squamous epithelium exposed to 4-NQO as revealed by measuring the silver-stained nucleolar organizer regions protein number/nucleus and 5'-bromodeoxyuridine-labeling index. Also, dietary AX and CX could reduce polyamine levels of oral mucosal tissues exposed to 4-NQO. These results indicate that AX and CX are possible chemopreventers for oral carcinogenesis, and such effects may be partly due to suppression of cell proliferation.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Canthaxanthin/therapeutic use , Carotenoids/therapeutic use , Mouth Neoplasms/prevention & control , beta Carotene/analogs & derivatives , Animals , Bromodeoxyuridine/metabolism , Male , Nucleolus Organizer Region , Precancerous Conditions/prevention & control , Rats , Rats, Inbred F344 , Xanthophylls
11.
Carcinogenesis ; 15(1): 15-9, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8293542

ABSTRACT

The chemopreventive effects of two xanthophylls, astaxanthin (AX) and canthaxanthin (CX), on urinary bladder carcinogenesis induced by N-butyl-N(4-hydroxybutyl)nitrosamine (OH-BBN) was investigated in male ICR mice. Mice were given 250 p.p.m. OH-BBN in drinking water for 20 weeks and after a 1 week interval with tap water, water containing AX or CX at a concentration of 50 p.p.m. was administered during subsequent 20 weeks. Other groups of mice were treated with AX or CX alone or untreated. At the end of the study (week 41), the incidences of preneoplastic lesions and neoplasms in the bladder of mice treated with OH-BBN and AX or CX were smaller than those of mice given OH-BBN. In particular, AX administration after OH-BBN exposure significantly reduced the incidence of bladder cancer (transitional cell carcinoma) (P < 0.003). However, the inhibition of the frequencies of such lesions in mice treated with OH-BBN and CX was not significant. Treatment with AX or CX also decreased the number/nucleus of silver-stained nucleolar organizer region proteins (AgNORs), a new index of cell proliferation, in the transitional epithelium exposed to OH-BBN. Preneoplasms and neoplasms induced by OH-BBN, and the antiproliferative potential, was greater for AX than CX. These results indicate that AX is a possible chemopreventive agent for bladder carcinogenesis and such an effect of AX may be partly due to suppression of cell proliferation.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Carotenoids/therapeutic use , Urinary Bladder Neoplasms/prevention & control , beta Carotene/analogs & derivatives , Animals , Body Weight/drug effects , Butylhydroxybutylnitrosamine , Canthaxanthin/therapeutic use , Liver/anatomy & histology , Liver/drug effects , Male , Mice , Mice, Inbred ICR , Nucleolus Organizer Region/drug effects , Organ Size/drug effects , Precancerous Conditions/chemically induced , Precancerous Conditions/prevention & control , Silver Staining , Urinary Bladder Neoplasms/chemically induced , Xanthophylls
12.
Cancer Lett ; 65(3): 209-13, 1992 Aug 31.
Article in English | MEDLINE | ID: mdl-1516035

ABSTRACT

The antitumorigenic effects of carotenoids, in addition to their immuno-enhancing effects, may occur by their direct action on growing tumor cells. To test this hypothesis the direct inhibitory effect of various concentrations of canthaxanthin (CX; 4,4'-diketo-beta-carotene), a non-provitamin A carotenoid, was tested on the in vitro growth of JB/MS, B16F10 melanomas and PYB6 fibrosarcoma and murine non-transformed NIH-3T3 (ATCC CRL 1658) cells. At concentrations of 1 x 10(-8) M up to 1 x 10(-4) M, CX significantly reduced the overall number of tumor cells. The greatest inhibition was observed at a CX concentration of 1 x 10(-4) M after 72 h and 96 h of incubation. However, CX had no inhibitory effect on the growth of the non-transformed NIH-3T3 cell line; rather it significantly enhanced growth of this cell line (P less than 0.05) after 96 h of incubation. Thus, the inhibitory action of CX on growing tumor cells appears to be due to its direct actions on tumor cells and not via its conversion to vitamin A or its immuno-enhancing effects.


Subject(s)
Canthaxanthin/pharmacology , Cell Division/drug effects , Fibrosarcoma/pathology , Melanoma, Experimental/pathology , Sarcoma, Experimental/pathology , 9,10-Dimethyl-1,2-benzanthracene , Analysis of Variance , Animals , Canthaxanthin/therapeutic use , Cell Line, Transformed , Cells, Cultured , Fibrosarcoma/chemically induced , Fibrosarcoma/drug therapy , Melanoma, Experimental/chemically induced , Melanoma, Experimental/drug therapy , Mice , Sarcoma, Experimental/chemically induced , Sarcoma, Experimental/drug therapy , Tumor Cells, Cultured/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...